Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Trial details
- Registry ID
- NCT05942911
- Phase
- Phase 2
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911 | Incannex Healthcare Ltd | Phase 2 | Terminated | 2024-10-28Actual |
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101 | Incannex Healthcare Ltd | Phase 2, Phase 3 | Completed | 2025-05-20Actual |
| DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.NCT07635563 | Incannex Healthcare Ltd | Phase 2 | Recruiting | 2027-04Estimated |
NCT07635563 · Incannex Healthcare Ltd
Not yet recruiting
Recruiting
NCT06146101 · Incannex Healthcare Ltd
Estimated
Actual
560 participants (planned)
121 participants (actual)
Estimated
Actual
Dec 2026
20 May 2025
Active not recruiting
Completed
NCT05942911 · Incannex Healthcare Ltd
Suspended
Terminated